Annexon, INC. (ANNX) — SEC Filings

Overview

Annexon, INC. (ANNX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Annexon, Inc. (ANNX) is a clinical-stage biopharmaceutical company focused on complement-mediated neuroinflammatory diseases, reporting no revenue and significant losses for the fiscal year ended December 31, 2025. The company is advancing two late-stage registrational programs: tanruprubart for Gui

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 37 neutral, 1 mixed. The dominant filing sentiment for Annexon, INC. is neutral.

Filing Type Overview

Annexon, INC. (ANNX) has filed 3 10-K, 15 8-K, 6 10-Q, 2 DEF 14A, 12 SC 13G/A, 5 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (43)

• Annexon Pushes Two Late-Stage Drugs Amidst Mounting Losses — 10-K · Mar 30, 2026 Risk: high
  Annexon, Inc. (ANNX) is a clinical-stage biopharmaceutical company focused on complement-mediated neuroinflammatory diseases, reporting no revenue and significa
• Annexon, Inc. Files 8-K: Material Definitive Agreement — 8-K · Nov 14, 2025 Risk: medium
  On November 12, 2025, Annexon, Inc. entered into a Material Definitive Agreement. The filing also indicates other events and the submission of financial stateme
• Annexon's R&D Surge Fuels 77% Net Loss Increase — 10-Q · Nov 10, 2025 Risk: high
  Annexon, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $158.4 million, up from $89.6 million in the sa
• Annexon's Q2 Net Loss Widens 66% on Soaring R&D Costs — 10-Q · Aug 14, 2025 Risk: high
  Annexon, Inc. reported a significant increase in net loss for the three and six months ended June 30, 2025, primarily driven by a substantial rise in research a
• Annexon, Inc. Files 8-K: Corporate Updates — 8-K · Jun 25, 2025 Risk: low
  On June 23, 2025, Annexon, Inc. filed an 8-K report detailing material modifications to the rights of security holders and financial statements/exhibits. The fi
• Annexon, Inc. Files 8-K on Security Holder Vote Matters — 8-K · Jun 9, 2025 Risk: low
  On June 5, 2025, Annexon, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not disclose specific
• Annexon Files Q1 2025 10-Q, Details Financials — 10-Q · May 12, 2025 Risk: medium
  Annexon, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including cash and cash equivalents and short
• Annexon Files Definitive Proxy Statement for 2025 Annual Meeting — DEF 14A · Apr 23, 2025 Risk: low
  Annexon, Inc. filed its definitive proxy statement on April 23, 2025, for its annual meeting on June 5, 2025. The filing concerns the election of directors and
• Annexon, Inc. Files 2024 10-K — 10-K · Mar 3, 2025 Risk: medium
  Annexon, Inc. filed its 2024 10-K on March 3, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Brisbane, California, operates
• Annexon, Inc. Files 8-K Report — 8-K · Jan 13, 2025 Risk: low
  On January 13, 2025, Annexon, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or oth
• Annexon, Inc. Files 8-K: Board and Executive Compensation Changes — 8-K · Jan 10, 2025 Risk: medium
  On January 10, 2025, Annexon, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing includes
• Annexon, Inc. Files 8-K Report — 8-K · Dec 16, 2024 Risk: low
  On December 16, 2024, Annexon, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or tr
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Annexon, Inc. Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: low
  Annexon, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial position, including cash and cash equivalents and comm
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G Filing — SC 13G · Oct 22, 2024
• Annexon, Inc. Files 8-K Report — 8-K · Oct 22, 2024 Risk: low
  On October 21, 2024, Annexon, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific m
• Annexon, Inc. Files 10-Q, Details R&D and ATM Program — 10-Q · Aug 12, 2024 Risk: medium
  Annexon, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the second quarter of 2024 and the
• Annexon, Inc. Files 8-K Report — 8-K · Aug 5, 2024 Risk: low
  On August 5, 2024, Annexon, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other
• Annexon Appoints New Chief Medical Officer — 8-K · Jun 25, 2024 Risk: medium
  On June 25, 2024, Annexon, Inc. filed an 8-K report detailing the appointment of Dr. David E. Rick as Chief Medical Officer, effective June 24, 2024. Dr. Rick b
• Annexon, Inc. Reports on Shareholder Vote Matters — 8-K · Jun 12, 2024 Risk: low
  Annexon, Inc. filed an 8-K on June 12, 2024, reporting on matters submitted to a vote of its security holders on June 5, 2024. The filing details the company's
• Annexon, Inc. Files 8-K for Material Definitive Agreement — 8-K · Jun 7, 2024 Risk: medium
  On June 5, 2024, Annexon, Inc. entered into a Material Definitive Agreement. The company, incorporated in Delaware with its principal executive offices in Brisb
• Annexon, Inc. Files 8-K Report — 8-K · Jun 4, 2024 Risk: low
  On June 4, 2024, Annexon, Inc. filed an 8-K report detailing a Regulation FD Disclosure and other events. The filing also includes financial statements and exhi
• Annexon, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk:
  Annexon, Inc. (ANNX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Annexon, Inc. filed its 10-Q report for the period ending March 31, 2024. The
• Annexon, Inc. Files 8-K Report — 8-K · May 7, 2024 Risk: low
  On May 7, 2024, Annexon, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific new ma
• Annexon, Inc. Announces 2024 Annual Meeting of Stockholders on June 5, 2024 — DEF 14A · Apr 25, 2024 Risk: low
  Annexon, Inc. (ANNX) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Annexon, Inc. will hold its 2024 Annual Meeting of Stockholders virtually
• SC 13G Filing — SC 13G · Apr 22, 2024
• Annexon, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 26, 2024 Risk: medium
  Annexon, Inc. (ANNX) filed a Annual Report (10-K) with the SEC on March 26, 2024. Annexon, Inc. filed its 2023 Form 10-K on March 26, 2024. The company is incor
• Annexon, Inc. Files 8-K Report — 8-K · Mar 4, 2024 Risk: low
  On March 1, 2024, Annexon, Inc. filed an 8-K report. The filing primarily serves as a notification of an event and includes financial statements and exhibits. N
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Point72 Takes 4.86M Share Stake in Annexon Inc. — SC 13G · Feb 12, 2024 Risk: low
  Point72 Asset Management, L.P. has disclosed a significant stake in Annexon, Inc., a pharmaceutical company, by acquiring shared voting and dispositive power ov
• Adage Capital Cuts Annexon Stake to 4.9% from 6.9% — SC 13G/A · Feb 7, 2024
  Adage Capital Partners, L.P. has updated its ownership stake in Annexon, Inc. (NASDAQ: ANNX) as of December 31, 2023, reducing its beneficial ownership from 6.9
• FMR LLC & Abigail Johnson Report 12.373% Stake in Annexon Inc. — SC 13G · Jan 10, 2024
  FMR LLC, a major investment management firm, and its principal owner, Abigail P. Johnson, have disclosed a significant stake in Annexon, Inc. As of December 31,
• Annexon Files Routine 8-K, Confirms Corporate Details — 8-K · Jan 8, 2024
  Annexon, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024. This filing is a routine update to disclose general corporat

Frequently Asked Questions